Target intelligence / Profile preview

Taurine up-regulated 1 (TUG1)

Target
TUG1
Molecular classification
Long non-coding RNA
01

Overview

Taurine up-regulated 1 (TUG1) is a highly conserved long non-coding RNA (lncRNA) located on chromosome 22q12.2, originally identified for its essential role in retinal development (PMID: 15802262). It functions as a molecular scaffold, interacting with the Polycomb Repressive Complex 2 (PRC2) to mediate epigenetic gene silencing and chromatin remodeling (PMID: 24703830). Additionally, TUG1 acts as a competitive endogenous RNA (ceRNA) or 'molecular sponge' that sequesters various microRNAs, thereby preventing them from inhibiting their target mRNAs and influencing pathways such as Wnt/beta-catenin and PI3K/Akt (PMID: 31110605). In clinical oncology, TUG1 is predominantly characterized as an oncogene, where its overexpression is linked to increased cell proliferation, migration, and poor prognosis in malignancies like glioblastoma and non-small cell lung cancer (PMID: 28656234). Beyond cancer, it is also implicated in metabolic diseases, notably showing protective roles in diabetic nephropathy when properly regulated. Therapeutic development currently focuses on using antisense oligonucleotides (ASOs) to trigger the degradation of TUG1 transcripts, aiming to suppress tumor growth and restore normal gene expression patterns (NCBI Gene ID: 55057).

Other names
Taurine up-regulated gene 1LINC00080NCRNA00080Long intergenic non-protein coding RNA 80
02

Mechanism of action

Antisense-mediated RNA degradation and RNA interference (RNAi) to reduce oncogenic lncRNA levels.

03

Biological functions

Regulation of transcriptionChromatin remodelingMicroRNA spongingCell proliferationApoptosis regulationCell cycle progressionRetinal development
04

Disease associations

CancerGlioblastomaNon-small cell lung cancerBreast cancerColorectal cancerDiabetic nephropathyCardiovascular disease
05

Safety considerations

Off-target effects of oligonucleotide therapiesSystemic delivery challengesPotential disruption of normal physiological functions in the retina and vasculature
06

Interacting drugs

TUG1-ASO (Antisense oligonucleotide)

1 more in the full profile.

07

Biomarkers

TUG1 expression level in tumor tissueCirculating TUG1 RNA in plasma

Beyond the preview

Go deeper on Taurine up-regulated 1 (TUG1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taurine up-regulated 1 (TUG1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call